TMEM161A

Across TCGA pan-cancer cohorts, TMEM161A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TMEM161A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TMEM161A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TMEM161A is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, LSCC, and COAD are the cancer types where TMEM161A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM161A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.418	<.001	11	view →
LSCC	Male	III,IV	+0.688	<.001	8	view →
COAD	All	All	+0.729	.007	6	view →
PDAC	All	All	−0.621	<.001	6	view →
CCRCC	Male	All	+0.257	.002	6	view →
LUAD	All	II,III,IV	+0.320	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TMEM161A–HNSC

Open the HNSC breakdown →